Jan Kaiserle

Jan Kaiserle

Medical Systems Advisor
Jan Kaiserle specializes in medical research and evidence-based medicine. He explores the latest advancements in medical science, clinical trials, and healthcare technologies to improve diagnosis, treatment, and disease prevention. His content bridges the gap between clinical research and practice, providing meaningful insights for healthcare professionals.
How Will Trump's Leadership Change FDA and Biotech Regulation?
Research & Development How Will Trump's Leadership Change FDA and Biotech Regulation?

The victory of Donald Trump in the U.S. presidential election has sparked widespread speculation about the potential changes within federal health agencies, particularly the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). Trump's past and potential future choices for

Rallybio's Battle: Navigating Financial Turbulence in Biotech Innovation
Management & Regulatory Rallybio's Battle: Navigating Financial Turbulence in Biotech Innovation

Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn

Innovent Biologics Faces Investor Backlash Over Misvalued Stake Sale
Management & Regulatory Innovent Biologics Faces Investor Backlash Over Misvalued Stake Sale

Innovent Biologics Inc. (1801.HK), a significant player in the Chinese biopharmaceutical sector, recently faced harsh backlash from investors due to a misstep in its strategy. The company aimed to strengthen its executives' dedication to its international unit, Fortvita, by selling a stake to the

Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development
Research & Development Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development

Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step

Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies
Research & Development Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies

Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors,

Can Trontinemab Be the Next Breakthrough in Alzheimer's Treatment?
Research & Development Can Trontinemab Be the Next Breakthrough in Alzheimer's Treatment?

Roche is considering seeking accelerated approval for its experimental Alzheimer’s drug, trontinemab, following promising early results. Trontinemab is currently in Phase 2 testing and has shown significant potential in reducing amyloid levels in the brain. This approach has been previously

How Will MilliporeSigma's $76M ADC Investment Change Cancer Treatment?
Research & Development How Will MilliporeSigma's $76M ADC Investment Change Cancer Treatment?

MilliporeSigma, a prominent player in the life sciences sector, has launched a transformative $76 million investment dedicated to expanding its ADC (antibody-drug conjugates) manufacturing capabilities at its St. Louis, Missouri facility. This monumental investment encapsulates the extensive

Can LakeShore Biopharma Sustain Growth After Regaining Nasdaq Compliance?
Management & Regulatory Can LakeShore Biopharma Sustain Growth After Regaining Nasdaq Compliance?

LakeShore Biopharma Co., Ltd (NASDAQ: LSB), a prominent biopharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement after experiencing non-compliance due to a prolonged period of its share price falling below $1.00. As of October 21, 2024, the company

How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?
Research & Development How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?

The recent FDA approval of Protega Pharmaceuticals Inc.'s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet marks a significant milestone in managing severe pain where alternative treatments fall short. ROXYBOND 10 mg stands out as the first FDA-approved abuse-deterrent IR

IPP's South Carolina Facility Earns Prestigious ASME 'R' Certification
Management & Regulatory IPP's South Carolina Facility Earns Prestigious ASME 'R' Certification

In a significant advancement for International Process Plants (IPP), the Universal Glasteel Equipment (UGE) subsidiary has attained the American Society of Mechanical Engineers (ASME) 'R' Certificate for its facility in Eastover, South Carolina. This recent recognition permits IPP to carry out

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later